Molecular biology for formyl peptide receptors in human diseases

被引:67
作者
Li, Yongsheng [1 ,2 ,3 ]
Ye, Duyun [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Pathophysiol, Wuhan 430030, Hubei, Peoples R China
[2] Brigham & Womens Hosp, Dept Anesthesiol, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA 02115 USA
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2013年 / 91卷 / 07期
基金
中国国家自然科学基金;
关键词
Formyl peptides; Chemoattractants; G protein-coupled receptors; Inflammation; N-FORMYLPEPTIDE RECEPTOR; C5A CHEMOATTRACTANT RECEPTORS; ASPIRIN-TRIGGERED LIPOXINS; INDUCED INSULIN-RESISTANCE; PROTEIN-COUPLED RECEPTORS; HUMAN GLIOBLASTOMA CELLS; AMYLOID-BETA PEPTIDE; ALZHEIMERS-DISEASE; GROWTH-FACTOR; HOST-DEFENSE;
D O I
10.1007/s00109-013-1005-5
中图分类号
Q3 [遗传学];
学科分类号
071007 [遗传学];
摘要
Leukocytes accumulate at sites of inflammation and immunological reaction in response to locally existing chemotactic mediators. The first chemotactic factors structurally defined were N-formyl peptides. Subsequently, numerous ligands were identified to activate formyl peptide receptors (FPRs) that belong to the seven-transmembrane G protein-coupled receptor superfamily. FPRs interact with this menagerie of structurally diverse pro- and anti-inflammatory ligands to possess important regulatory effects in multiple diseases, including inflammation, amyloidosis, Alzheimer's disease, prion disease, acquired immunodeficiency syndrome, obesity, diabetes, and cancer. How these receptors recognize diverse ligands and how they contribute to disease pathogenesis and host defense are basic questions currently under investigation that would open up new avenues for the future management of inflammation-related diseases.
引用
收藏
页码:781 / 789
页数:9
相关论文
共 100 条
[1]
Inflammation and Alzheimer's disease [J].
Akiyama, H ;
Barger, S ;
Barnum, S ;
Bradt, B ;
Bauer, J ;
Cole, GM ;
Cooper, NR ;
Eikelenboom, P ;
Emmerling, M ;
Fiebich, BL ;
Finch, CE ;
Frautschy, S ;
Griffin, WST ;
Hampel, H ;
Hull, M ;
Landreth, G ;
Lue, LF ;
Mrak, R ;
Mackenzie, IR ;
McGeer, PL ;
O'Banion, MK ;
Pachter, J ;
Pasinetti, G ;
Plata-Salaman, C ;
Rogers, J ;
Rydel, R ;
Shen, Y ;
Streit, W ;
Strohmeyer, R ;
Tooyoma, I ;
Van Muiswinkel, FL ;
Veerhuis, R ;
Walker, D ;
Webster, S ;
Wegrzyniak, B ;
Wenk, G ;
Wyss-Coray, T .
NEUROBIOLOGY OF AGING, 2000, 21 (03) :383-421
[2]
Chemoattractant receptor cross-desensitization [J].
Ali, H ;
Richardson, RM ;
Haribabu, B ;
Snyderman, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (10) :6027-6030
[3]
ALI H, 1993, J BIOL CHEM, V268, P24247
[4]
Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity [J].
Aliberti, J ;
Hieny, S ;
Sousa, CRE ;
Serhan, CN ;
Sher, A .
NATURE IMMUNOLOGY, 2002, 3 (01) :76-82
[5]
IKK-β links inflammation to obesity-induced insulin resistance [J].
Arkan, MC ;
Hevener, AL ;
Greten, FR ;
Maeda, S ;
Li, ZW ;
Long, JM ;
Wynshaw-Boris, A ;
Poli, G ;
Olefsky, J ;
Karin, M .
NATURE MEDICINE, 2005, 11 (02) :191-198
[6]
Cancer and Inflammation: Implications for Pharmacology and Therapeutics [J].
Balkwill, F. ;
Mantovani, A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (04) :401-406
[7]
BAO L, 1992, Genomics, V13, P437, DOI 10.1016/0888-7543(92)90265-T
[8]
A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis [J].
Betten, Å ;
Bylund, J ;
Cristophe, T ;
Boulay, F ;
Romero, A ;
Hellstrand, K ;
Dahlgren, C .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (08) :1221-1228
[9]
Brown DR, 1997, HISTOL HISTOPATHOL, V12, P883
[10]
Cutting Edge: A Critical Role for the G Protein-Coupled Receptor mFPR2 in Airway Inflammation and Immune Responses [J].
Chen, Keqiang ;
Le, Yingying ;
Liu, Ying ;
Gong, Wanghua ;
Ying, Guoguang ;
Huang, Jian ;
Yoshimura, Teizo ;
Tessarollo, Lino ;
Wang, Ji Ming .
JOURNAL OF IMMUNOLOGY, 2010, 184 (07) :3331-3335